venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukemi, lymfocytisk, kronisk, b-cell - antineoplastiska medel - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
itrakonazol ebb 100 mg kapsel, hård
ebb medical ab - itrakonazol - kapsel, hård - 100 mg - itrakonazol 100 mg aktiv substans; sockersfärer hjälpämne
voriconazole sandoz 200 mg filmdragerad tablett
sandoz a/s - vorikonazol - filmdragerad tablett - 200 mg - laktosmonohydrat hjälpämne; vorikonazol 200 mg aktiv substans - vorikonazol
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.
posaconazole accord
accord healthcare s.l.u. - posakonazol - mycoses - antimykotika för systemisk användning - posaconazole accord is indicated for use in the treatment of the following fungal infections in adults:invasive aspergillosis;fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refraktäritet definieras som utveckling av infektion eller utebliven förbättring efter en vistelse på minst 7 dagar före terapeutiska doser av effektiv antimykotisk terapi. posaconazole accord är också indicerat för profylax av invasiva svampinfektioner i följande patienter: patienter som får syndernas-induktion kemoterapi vid akut myeloisk leukemi (aml) eller myelodysplastiskt syndrom (mds) förväntas resultera i långvarig neutropeni och som löper hög risk att utveckla invasiv svampinfektion;hematopoetisk stamcellstransplantation (hsct) mottagare som behandlas med höga doser av immunosuppressiv terapi för graft versus host sjukdom och som är i hög risk att utveckla invasiv svampinfektion.
posaconazole stada 100 mg enterotablett
stada arzneimittel ag - posakonazol - enterotablett - 100 mg - posakonazol 100 mg aktiv substans; xylitol hjälpämne
vorikonazol ebb 200 mg filmdragerad tablett
ebb medical ab - vorikonazol - filmdragerad tablett - 200 mg - laktosmonohydrat hjälpämne; vorikonazol 200 mg aktiv substans
ventolin diskus 0,2 mg/dos inhalationspulver, avdelad dos
medartuum ab - salbutamolsulfat - inhalationspulver, avdelad dos - 0,2 mg/dos - laktosmonohydrat hjälpämne; salbutamolsulfat 0,24 mg aktiv substans - salbutamol
ventoline 1 mg/ml lösning för nebulisator
glaxosmithkline ab - salbutamolsulfat - lösning för nebulisator - 1 mg/ml - salbutamolsulfat 1,2 mg aktiv substans - salbutamol
ventoline 2 mg/ml lösning för nebulisator
glaxosmithkline ab - salbutamolsulfat - lösning för nebulisator - 2 mg/ml - salbutamolsulfat 2,4 mg aktiv substans - salbutamol